GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Phase 3

VK2735

VK2735

Company
Viking Therapeutics
Mechanism
dual GLP-1/GIP
Route
Oral & injectable
Recruiting trials
None currently listed

Efficacy results: Not yet reported

Next milestone: VANQUISH-2 Phase 3 data (2026-Q3, estimated)

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT05203237

    Phase 1 Study to Evaluate the Safety and Tolerability of VK2735

    Not yet reported Viking Therapeutics, Inc. 92 participants Est. completion 2024-12-03 1 site Stand-alone
    MASH Other conditions: Weight Loss
    View official trial listing →
  • Completed NCT NCT06068946

    VK2735 for Weight Management Phase 2

    Not yet reported Viking Therapeutics, Inc. 176 participants Est. completion 2024-04-02 20 sites Stand-alone
    Other conditions: Weight Loss
    View official trial listing →
  • Completed NCT NCT06828055

    VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

    Not yet reported Viking Therapeutics, Inc. 280 participants Est. completion 2025-08-15 15 sites Stand-alone
    Other conditions: Weight Loss
    View official trial listing →
  • Active, not recruiting NCT NCT07104383

    VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

    Not yet reported Viking Therapeutics, Inc. 1100 participants Est. completion 2027-08-01 127 sites Stand-alone
    Other conditions: Weight Loss
    View official trial listing →
  • Active, not recruiting NCT NCT07104500

    VK2735 for Weight Management Phase 3

    Not yet reported Viking Therapeutics, Inc. 4500 participants Est. completion 2027-08-01 137 sites Stand-alone
    Other conditions: Weight Loss
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.